Compare Advance Auto Parts, Inc. (AAP) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Biogen Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.07 (market cap $3.19B), while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 9.4× Advance Auto Parts, Inc.'s market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| AAP | BIIB | |
|---|---|---|
Market Cap | $3.19B | $30.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $216.63 |
52-Week Low | $38.75 | $128.93 |
Enterprise Value | $5.47B | $37.20B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.52, down 3.97% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.77 versus $0.39 expected, but profitability remains thin with a net income margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain improvements, as noted in recent news (The Motley Fool, August 2026).
The outlook is cautious; while valuation appears reasonable with a P/S of 0.37 and analysts set a $61.30 consensus target, weak cash flow from operations and high debt pose risks. Investor sentiment is neutral amid restructuring efforts, but margin expansion and successful execution are critical for sustained recovery.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
